Sangamo completes acquisition of TxCell

04-Dec-2018 - Sangamo Therapeutics, Inc. announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market. “The acquisition of TxCell immediately positions Sangamo as the leader in CAR-Treg development,” said Sandy Macrae, CEO ...

Zelluna Immunotherapy appoints Miguel Forte as Chief Executive Officer

Appointment to drive Zelluna through next stage of international clinical-phase development

03-Nov-2017 - Zelluna Immunotherapy,the biotechnology company specializing in T-cell receptor (TCR) immunotherapies targeting a broad range of solid cancers with a high unmet medical need, today announces the appointment of Miguel Forte as chief executive officer (CEO). “Zelluna is developing a unique ...

Hybrigenics’ inecalcitol gets Orphan Drug designation for the treatment of Acute Myeloid Leukemia in the United States

18-Aug-2015 - Hybrigenics announcesthe Orphan Drug designation by the American Food and Drug Administration of inecalcitol for the treatment of acute myeloid leukemia (AML) in the United States. This favourable decision is based onin vitroandin vivopreclinical evidence showing the synergy between ...

TxCell receives Fast Track Designation from FDA for Ovasave

TxCell’s lead product designated for the treatment of moderate to severe Crohn’s disease

29-Jul-2015 - TxCell SA announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to TxCell’s lead product Ovasave(R) for the treatment of moderate to severe Crohn’s disease. Ovasave already has an active IND (Investigational New Drug) with the FDA. The FDA Fast ...

TxCell raises approx. EUR 8 million through a private placement of 10 percent of its common shares

24-Jul-2015 - TxCell SA announced the successful completion of a private placement of a total amount of approximately EUR 8 million.“We are extremely pleased to welcome on board new, mostly international, institutional investors, as shareholders. Whilst TxCell operates in a mainstream technology, cellular ...

TxCell announces a temporary partial hold of activities at its pilot manufacturing unit

25-Jun-2015 - TxCell SA announced that it has temporarily put its pilot manufacturing facility activities at Besançon, France on partial hold. The decision was made in agreement with the French regulator, Agence Nationale de Sécurité du Médicament, (ANSM).The decision was made so that TxCell could take action ...

TxCell appoints Chief Executive Officer

29-Apr-2015 - TxCell SA announces the appointment of Stéphane Boissel as Chief Executive Officer (CEO). In addition, Dr. Miguel Forte, previously SVP Clinical and Regulatory, is promoted to Chief Operating Officer. Stéphane Boissel succeeds Damian Marron, who has resigned from the company to pursue other ...

TxCell receives EU Orphan Drug Designation for Col-Treg in the treatment of non-infectious uveitis

22-Dec-2014 - TxCell SA announced that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis."Obtaining orphan drug ...

TxCell announces start of phase IIb clinical trial with Ovasave for refractory Crohn’s disease

05-Dec-2014 - TxCell SA announced that it has enrolled the first patient in its phase IIb clinical trial of its lead product Ovasave(R) in refractory Crohn’s disease. TxCell has received approval for this multi-center, multinational trial from the regulatory authorities in all six European countries in which ...

Polyplus-transfection and Blue Sky BioServices sign a research and commercial license agreement for use of PEI-based transfection technologies

03-Nov-2014 - Polyplus-transfection SA and Blue Sky BioServices announced a non-exclusive, research and commercial license agreement. Polyplus has granted Blue Sky BioServices a licence to use Polyethylenimine (PEI) for in vitro transfection applications. Blue Sky BioServices, has become the 17th sub-licensee, ...